NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board

Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. Alexandra M. Miller to its scientific advisory board, enhancing its expertise in neuro-oncology [2][3] - Dr. Miller's background in developing liquid biopsy assays for CNS tumors will support NeOnc's clinical trials for its therapeutics NEO100™ and NEO212™ [3][4] - The company is expanding its global trial network, with new sites opening in the Middle East and India, indicating growth in its research capabilities [4] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system cancers, particularly addressing challenges related to the blood-brain barrier [6] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates, with patent protections extending to 2038 [6] - NEO100™ and NEO212™ are currently in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status [6]